KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Other financing activities (2016 - 2024)

Historic Other financing activities for Biomarin Pharmaceutical (BMRN) over the last 15 years, with Q4 2024 value amounting to -$94000.0.

  • Biomarin Pharmaceutical's Other financing activities fell 10888.89% to -$94000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was -$94000.0, marking a year-over-year increase of 9699.49%. This contributed to the annual value of -$3.2 million for FY2024, which is 3897.64% down from last year.
  • As of Q4 2024, Biomarin Pharmaceutical's Other financing activities stood at -$94000.0, which was down 10888.89% from -$3.0 million recorded in Q3 2024.
  • In the past 5 years, Biomarin Pharmaceutical's Other financing activities ranged from a high of $943000.0 in Q2 2020 and a low of -$3.0 million during Q3 2024
  • For the 5-year period, Biomarin Pharmaceutical's Other financing activities averaged around -$518750.0, with its median value being -$43500.0 (2023).
  • Per our database at Business Quant, Biomarin Pharmaceutical's Other financing activities soared by 24011.89% in 2020 and then tumbled by 8693333.33% in 2022.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Other financing activities stood at $943000.0 in 2020, then plummeted by 99.68% to $3000.0 in 2021, then plummeted by 86933.33% to -$2.6 million in 2022, then surged by 98.27% to -$45000.0 in 2023, then tumbled by 108.89% to -$94000.0 in 2024.
  • Its Other financing activities stands at -$94000.0 for Q4 2024, versus -$3.0 million for Q3 2024 and -$18000.0 for Q2 2024.